Does warfarin prevent venous thromboembolic events in aPL-positive patients?

MOspace/Manakin Repository

Breadcrumbs Navigation

Does warfarin prevent venous thromboembolic events in aPL-positive patients?

Please use this identifier to cite or link to this item: http://hdl.handle.net/10355/3608

[+] show full item record


Title: Does warfarin prevent venous thromboembolic events in aPL-positive patients?
Author: Mazzone, Michael F.; Jamieson, Barbara
Keywords: lupus
anticardiolipin antibody
aspirin
Date: 2007-04
Publisher: Family Physicians Inquiries Network
Citation: Journal of Family Practice, 56(4) 2007: 309+.
Abstract: Yes, warfarin is effective in the secondary prevention of venous thromboembolic events (VTEs) for patients positive for lupus anticoagulant or anticardiolipin antibody (also known as antiphospholipid antibodies [aPL]) (strength of recommendation [SOR]: B, single cohort study, extrapolation from other RCTs). Patients should be treated for at least a year (SOR: C, consensus statement), and possibly indefinitely, with warfarin (SOR: B, small clinical trials and cohort studies). Moderate-intensity therapy (international normalized ratio [INR] range, 2.0-3.0) appears to be the best balance between risks and benefits (SOR: B, based on meta-analysis of 2 small randomized control trials.
URI: http://hdl.handle.net/10355/3608

This item appears in the following Collection(s)

[+] show full item record